Lipoprotein X in autoimmune liver disease causing interference in routine and specialist biochemical investigations

References

• Heimerl S, Boettcher A, Kaul H, et al. Lipid profiling of lipoprotein X: implications for dyslipidemia in cholestasis. Biochim Biophys Acta. 2016;1861(8 Pt A):681-687.10.1016/j.bbalip.2016.04.016
   PubMed Web of Science ®Google Scholar
• McDowell IF, Wisdom GB, Trimble ER. Apolipoprotein E phenotype determined by agarose gel electrofocusing and immunoblotting. Clin Chem. 1989;35(10):2070–2073.
   Web of Science ®Google Scholar
• Nemes K, Aberg F, Gylling H, et al. Cholesterol metabolism in cholestatic liver disease and liver transplantation: from molecular mechanisms to clinical implications. World J Hepatol. 2016;8(22):924–932.10.4254/wjh.v8.i22.924
   Web of Science ®Google Scholar
• Narayanan S. Lipoprotein-X. CRC Crit Rev Clin Lab Sci. 1979;11(1):31–51.
   PubMed Web of Science ®Google Scholar
• Brandt EJ, Regnier SM, Leung EK, et al. Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis. Clin Lipidol. 2015;10(4):305–312.10.2217/clp.15.23
   Web of Science ®Google Scholar
• Saeedi R, Li M, Frohlich J. A review on lecithin:cholesterol acyltransferase deficiency. Clin Biochem. 2015;48(7–8):472–475.10.1016/j.clinbiochem.2014.08.014
   PubMed Web of Science ®Google Scholar
• Miller JP. Dyslipoproteinaemia of liver disease. Baillieres Clin Endocrinol Metab. 1990;4(4):807–832.10.1016/S0950-351X(05)80080-1
   Google Scholar
• Crook MA. Lipoprotein X: clinical implications. Ann Clin Biochem. 2013;50(2):93–94.10.1177/0004563213478804
   Web of Science ®Google Scholar
• Ossoli A, Neufeld EB, Thacker SG, et al. Lipoprotein X Causes Renal Disease in LCAT Deficiency. PLoS One. 2016;11(2):e0150083.10.1371/journal.pone.0150083
   Web of Science ®Google Scholar
• Sivakumar T, Chaidarun S, Lee HK, et al. Multiple lipoprotein and electrolyte laboratory artifacts caused by lipoprotein X in obstructive biliary cholestasis secondary to pancreatic cancer. J Clin Lipidol. 2011;5(4):324–328.10.1016/j.jacl.2011.04.004
   Web of Science ®Google Scholar
• Hussain I, Ahmad Z, Garg A. Extreme hypercholesterolemia presenting with pseudohyponatremia – a case report and review of the literature. J Clin Lipidol. 2015;9(2):260–264.10.1016/j.jacl.2014.11.007
   Web of Science ®Google Scholar
• le RM, Burgess LJ, Marais AD. Pseudohyponatraemia in a patient with obstructive jaundice. Clin Chim Acta 2006; 366(1-2):357-360.
   Web of Science ®Google Scholar
• Ravella S, Lefavour GS, Carayannopoulos MO, et al. Hyponatremia in a patient with obstructive jaundice. Kidney Int. 2015;88(4):921–922.10.1038/ki.2015.15
   Web of Science ®Google Scholar
• Herzum I, Giehl C, Soufi M, et al. Interference in a homogeneous assay for low-density lipoprotein cholesterol by lipoprotein X. Clin Chem Lab Med. 2007;45(5):667–671.
   Web of Science ®Google Scholar
• Futatsugi A, Hidaka E, Kubota N, et al. Abnormal serum total protein measurement by Lipoprotein-X in an infant with biliary atresia. Rinsho Byori. 2015;63(11):1271–1276.
   Google Scholar
• Abe M, Kurosawa H, Sato R, Ito K, Tomono Y, Manita D, et al. Differences in measured values among homogenous assay reagents of LDL-C in LP-X positive serum samples. Rinsho Byori. 2015;63(3):312–318.
   Google Scholar
• Mahley RW. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J Mol Med (Berl). 2016;94(7):739–746.10.1007/s00109-016-1427-y
   PubMed Web of Science ®Google Scholar
• Narayanan S. Biochemistry and clinical relevance of lipoprotein X. Ann Clin Lab Sci. 1984;14(5):371–374.
   Web of Science ®Google Scholar
• Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis. 2007;194(2):293–299.10.1016/j.atherosclerosis.2006.11.036
   PubMed Web of Science ®Google Scholar
• Chang PY, Lu SC, Su TC, et al. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res. 2004;45(11):2116–2122.10.1194/jlr.M400229-JLR200
   PubMed Web of Science ®Google Scholar
• Lowyck I, Fevery J. Statins in hepatobiliary diseases: effects, indications and risks. Acta Gastroenterol Belg. 2007;70(4):381–388.
   Web of Science ®Google Scholar
• Awan Z, Bailey D, Hafiane A, et al. Acquired severe hypercholesterolemia and hypoalphalipoproteinemia. J Clin Lipidol. 2009;3(6):393–397.10.1016/j.jacl.2009.10.001
   Web of Science ®Google Scholar